Accessibility Menu
 
Ascendis Pharma A/s logo

Ascendis Pharma A/s

(NASDAQ) ASND

Current Price$221.89
Market Cap$13.91B
Since IPO (2026)-8%
5 Year+64%
1 Year+38%
1 Month+4%

Ascendis Pharma A/s Financials at a Glance

Market Cap

$13.91B

Revenue (TTM)

$717.81M

Net Income (TTM)

$227.72M

EPS (TTM)

$-4.20

P/E Ratio

-54.00

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$221.89

Volume

2,222,365.546

Open

$227.25

Previous Close

$222.08

Daily Range

$221.00 - $228.15

52-Week Range

$150.89 - $250.74

ASND News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ascendis Pharma A/s

Industry

Biotechnology

CEO

Jan Møller Mikkelsen

Headquarters

Hellerup, 2900, DK

ASND Financials

Key Financial Metrics (TTM)

Gross Margin

86%

Operating Margin

-19%

Net Income Margin

-32%

Return on Equity

0%

Return on Capital

-59%

Return on Assets

-17%

Earnings Yield

-1.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$13.91B

Shares Outstanding

61.38M

Volume

2.22M

Avg. Volume

674.39K

Financials (TTM)

Gross Profit

$588.53M

Operating Income

$130.89M

EBITDA

$113.90M

Operating Cash Flow

$51.77M

Capital Expenditure

$8.15M

Free Cash Flow

$43.62M

Cash & ST Invst.

$615.78M

Total Debt

$871.41M

Ascendis Pharma A/s Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$245.18M

+41.0%

Gross Profit

$217.98M

+36.3%

Gross Margin

88.91%

N/A

Market Cap

$13.91B

N/A

Market Cap/Employee

$13.68M

N/A

Employees

1,017

N/A

Net Income

$33.25M

+13.6%

EBITDA

$14.58M

+138.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$255.64M

+13.9%

Accounts Receivable

$157.63M

-5.2%

Inventory

$301.40M

+2.0%

Long Term Debt

$385.09M

+5.5%

Short Term Debt

$486.32M

-1.1%

Return on Assets

-17.49%

N/A

Return on Invested Capital

-58.50%

N/A

Free Cash Flow

$67.37M

+176.9%

Operating Cash Flow

$70.67M

+181.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BBIOBridgeBio Pharma, Inc.
$69.66-6.52%
IONSIonis Pharmaceuticals, Inc.
$71.78-0.62%
MDGLMadrigal Pharmaceuticals, Inc.
$516.69-0.65%
EXELExelixis, Inc.
$44.93+0.63%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$11.30+0.05%
POETPoet Technologies
$8.03+0.01%
TQQQProShares Trust - ProShares UltraPro Qqq
$60.74-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.14-0.01%

Questions About ASND

What is the current price of Ascendis Pharma A/s?

Ascendis Pharma A/s is trading at $222.08 per share.

What is the 52-week range for Ascendis Pharma A/s?

Over the past 52 weeks, Ascendis Pharma A/s has traded between $150.89 and $250.74.

How much debt does Ascendis Pharma A/s have?

As of the most recent reporting period, Ascendis Pharma A/s reported total debt of $1.02B.

How much cash does Ascendis Pharma A/s have on hand?

Ascendis Pharma A/s reported $723.51M in cash and cash equivalents in its most recent financial results.

What is Ascendis Pharma A/s’s dividend yield?

Ascendis Pharma A/s does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.